A study has been published highlighting that the Sensinel cardiopulmonary management (CPM) system by Analog Devices (ADI) effectively detects signs of fluid overload in the heart and could be used to monitor patients and prevent hospital admissions.
The results, published in the European Journal of Heart Failure, show that the device performed well, and was able to detect the changes in fluid and weight in patients as patients had fluid removed. Researchers for the study believe that this new wearable sensor device could be used as a method of monitoring patients with heart failure and detecting fluid overload, as well as potentially reducing hospital admissions. The amount of fluid in the body is an important warning sign of congestive heart failure.
The data was also presented at the European Society of Cardiology’s Heart Failure Congress in Lisbon, Portugal, on 12 May.
The Sensinel CPM System is a non-invasive, remote management and wearable device. It is designed to capture vital cardiopulmonary measurements for chronic disease management such as heart failure. The US Food and Drug Administration (FDA)-approved device allows patients to self-apply and wear for three to five minutes at home. It then collects health data and transmits it to the Sensinel CPM Cloud Platform through a cellular connection.
Patients with heart failure have trouble pumping blood around the body, which causes fluid to build up. According to a report on GlobalData’s Pharma Intelligence Center, there will be 3,708,285 cases of heart failure in the seven major markets (UK, US, Germany, France, Spain, Italy, and Japan).
The 66-patient CONGEST-HF study enrolled patients who were admitted to the Queen Elizabeth University Hospital (QEUH), Glasgow, and the Scottish National Advanced Heart Failure Unit. NHS Greater Glasgow and Clyde Research and Innovations sponsored the trial, with ADI providing funding to the University of Glasgow for the design and conduct of the study.
Pardeep Jhund, the senior author of the study, said: “The next step will be to conduct a large trial to determine if the device can detect fluid accumulation in patients who use it at home and provide sufficient warning so that we can reduce hospitalisations in those patients who use the device.”
The use of wearable devices in the heart disease space is increasing. In July 2023, the first US patients were implanted with FIRE1’s sensor device that monitors the amount of fluid in the body. The device is implanted into the vena cava using a small catheter. It is inserted in collapsed form and expands to full size upon entering the vein, continuously measuring the size of the vessel. According to GlobalData, the remote patient monitoring market will generate $760m by 2030.
